Shanghai Pharmaceuticals Holding Co., Ltd. (02607) has announced plans to host an Extraordinary General Meeting on 9 December 2025 in Shanghai. Key proposals include abolishing the supervisory board, amending the Articles of Association and its appendices, revising the implementation rules of the cumulative voting system, and updating administrative measures for raised funds. The agenda also features a 2025 interim profit distribution plan proposing a cash dividend of RMB1.20 (tax inclusive) for every ten shares, based on 3,708,361,809 shares recorded as of 30 June 2025.

Under the proposals, the previous supervisory board structure would be replaced, with corresponding revisions to the Articles of Association clarifying internal governance, committee functions, and new processes for overseeing company operations. Amendments to the implementation rules of the cumulative voting system are designed to ensure equitable voting when electing directors. Updates to the administrative measures for raised funds primarily address usage guidelines, supervision agreements, and disclosure requirements. Shanghai Pharmaceuticals plans to finalize all items through a shareholder vote at the upcoming EGM.